Real world evidence lead endo-metabolic, global rare diseases
Pubblicato il 30-08-2026 - Chiesi Farmaceutici in Italia
Real World Evidence Lead Endo-Metabolic, Global Rare Diseases Date: 22 Jul 2026 Department: GRD Global Medical Affairs Business Area: Mktg, Market Access, Bus. Affair Job Type: Direct Employee Contract Type: Permanent Location: Europe, IT About us Chiesi is an international research-focused biopharmaceutical group with 90 years' experience, operating in more than 30 countries, with its Headquarter in Parma, Italy. This is what drives us as we research, develop, and market innovative drugs across our main therapeutic areas. At Chiesi we are thinking generations ahead, driving sustainable innovation with purpose. As a Vantaggi Corporation and a certified B Corp, we have embedded sustainability in our bylaws and continuously measure our impact. We believe our differences make us stronger. Chiesi Global Rare Diseases Chiesi Global Rare Diseases is a Chiesi Group's business unit established in February 2020 and focused on research, development and commercialization of treatments and patient support services for rare and ultra‐rare disorders,
many of whom have limited or no treatments available. This unit is based in Boston, Massachusetts, with a strong synergy with the headquarters in Parma. Rare unit has a focus on research and product development for lysosomal storage diseases, rare hematology, ophthalmology disorders and rare immunodeficiencies. The unit is also a dedicated partner with global leaders in scientific research, patient advocacy and care. What we are looking for This is what you will do Reporting to the VP, RWE, the Real World Evidence Lead Endocrine‐Metabolic (Endo‐Met) is responsible for leading and executing the global RWE strategy and vision for the Endo‐Met Portfolio within GRD. The role ensures the strategy, creation and updating of the integrated evidence generation plan (IEGP), in alignment with cross‐functional partners to meet research and commercial objectives. The role drives enterprise‐level RWE impact, including building strategic data partne